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Abstract. Background: Poly (ADP-ribose) polymerase
(PARP) inhibitors and histone deacetylase (HDAC) inhibitors
are new promising anticancer drugs. The aim of the present
study was to investigate the effect of combination treatment
with PARP inhibitor PJ34 and HDAC inhibitor vorinostat on
human leukemia cell lines. Materials and Methods:
Proliferation, apoptosis, mitochondrial membrane potential
(ψm) and cell cycle were assessed in HL60, MOLT4, U937
and K562 cells cultured with each drug alone and with both
drugs. Results: PJ34 alone at 0.2-0.4 μM did not influence
the examined parameters. Vorinostat alone at 1.0-2.5 μM
reduced proliferation, increased apoptosis rate, lowered ψm
and increased the percentage of sub-G1 cells in all cell lines.
Incubation with both drugs caused further inhibition of
proliferation and increase in apoptosis associated with a
decrease in ψm and sub-G1 arrest in HL60, MOLT4 and
K562 cells, but not in U937 cells. Conclusion: Combination
of PARP and HDAC inhibitors can exert a synergistic effect
on inhibition of proliferation and increase apoptosis of
leukemia cells.
Targeted therapies have become a hot topic in anticancer
research. Recently, considerable interest has been given on
drugs that target histone-modifying enzymes and cells with
impaired DNA repair: histone deacetylase (HDAC) inhibitors
and poly (ADP-ribose) polymerase (PARP) inhibitors.
PARP is a family of nuclear enzymes involved in DNA
damage recognition and repair. PARP1 is the best known
protein of this family which participates in single-strand
breaks repair and may also be involved in the repair of
double-strand breaks through the homologous recombination
pathway (1, 2). Inhibition of its activity results in
accumulation of single-strand breaks and ultimately leads to
double-strand breaks. PARP inhibitors have been extensively
studied as agents preventing DNA repair in cancer cells,
especially in cells with mutated breast cancer-associated
gene-1 and -2 (BRCA1/2), involved in the repair of double-
strand breaks (3). However, PARP inhibitors, such as PJ34,
ABT-888 and KU-0058948, have been found to exert anti-
proliferative and pro-apoptotic effects when used alone or in
combination with potential chemotherapeutic agents in
various cancer types. PJ34 enhanced the antitumor effects of
doxorubicin in HeLa cells (4). ABT-888 potentiated
irinotecan treatment of colon cancer cell lines (5) and
enhanced the cytotoxic effect of temozolomide in leukemia
cells in vitro and in a melanoma model in vivo (6, 7). PJ34
and KU-0058948 induced cell-cycle arrest and apoptosis of
primary myeloid leukemia cells and cell lines in vitro (8). 
HDAC inhibitors are promising new anticancer agents
with low toxicity toward normal non-malignant cells. They
inhibit deacetylation of proteins, especially those involved
in cell proliferation, differentiation and apoptosis (9).
Vorinostat is a broad-spectrum HDAC inhibitor used in
clinical trials (10, 11) shown to induce production of
reactive oxygen species, growth arrest and apoptosis of
leukemia cells (12). It has been postulated that the effect of
vorinostat on cancer cells is due to induction of DNA
damage, including single- and double-strand breaks (12, 13).
Furthermore, impaired repair of double-strand DNA breaks
is a common feature of acute myeloid leukemia and
myelodysplastic syndromes (14).
To our knowledge, there are only two studies
demonstrating the effects of combinatorial treatment of
tumor cells with PARP inhibitors and HDAC inhibitors (8,
15) and only one of them concerns leukemia cells. Gaymes
et al. demonstrated that the HDAC inhibitor, MS275,
enhanced the cytotoxic effect of the PARP inhibitor KU-
0058948 in leukemia cells in vitro (8). Therefore, the aim of
the present study was to demonstrate the effect of PARP1
inhibitor PJ34 in combination with DNA-damaging HDAC
inhibitor vorinostat on proliferation, apoptosis and cell cycle
of human leukemia cell lines.
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Materials and Methods
Drugs. PJ34 was purchased from Merck Chemicals (Darmstadt,
Germany) and vorinostat from Sigma Chemical Co. (St. Louis, MO,
USA). Stock solutions of drugs were aliquoted and kept frozen at
−20ºC. 
Cell culture. Cultures of HL60, MOLT4, U937 and K562 cells (all
obtained from ECACC, Salisbury, UK) were maintained in RPMI-
1640 medium supplemented with 10% fetal bovine serum ( FBS),
2 mM L-glutamine and 50 μg/ml gentamicin (all from Life
Technologies, Paisley, UK). Cells were cultured at 37˚C in a
humidified 5% CO2 atmosphere and used for experiments in the
exponential growth phase.
PARP activity assay. Cellular PARP activity was measured using the
Universal Colorimetric PARP Assay kit (Trevigen, Gaithersburg,
MD, USA) according to the manufacturer’s instructions. The assay
measures incorporation of biotinylated poly(ADP-ribose) into
histone proteins in 96-well plates. Briefly, cell lysates were prepared
from 5×106 cells and 30 μg of protein was added in triplicates to
the wells containing PARP buffer and PARP cocktail. Following
incubation at room temperature for 1 h and a short wash with 0.1%
Triton X-100, streptavidin horseradish peroxidase was added to the
wells, and the mixture was incubated at room temperature for 20
min. After washing the plate with 0.1% Triton X-100, TACS-
Sapphire colorimetric substrate was added and plate was incubated
in the dark for 30 min. Absorbance of samples was measured at 450
nm using microplate fluorescence reader FL600 (Bio-Tek
Instruments, Inc., Winooski, VT , USA). 
PARP activity was calculated using the standard curve obtained
from readings of the standards and expressed as arbitrary
absorbance units per mg of protein.
Cell proliferation and viability assays. Cell growth was assessed by
the alamar blue assay (Biosource, Camarillo, CA, USA), as described
previously (16). Briefly, the cells were seeded into 96-well plate at a
density of 2×104 cells per well (100 μl) in culture medium alone or
supplemented with the studied drugs and incubated for a specified
amount of time (48 h with PJ34 and 24 h with vorinostat). After the
incubation, alamar blue was added to the wells to a final concentration
of 10% and the plates were incubated for 4 h at 37˚C in a humidified
atmosphere with 5% CO2. The intensity of fluorescence emitted due to
reduction of alamar blue was measured using FL600 microplate reader
(excitation: 530 nm, emission: 590 nm). 
Cell viability was determined using the trypan blue exclusion
method. Cell proliferation and viability were expressed as the
percentage of that of the control (100%).
Apoptosis assay. Apoptotic cells were analyzed using Muse Annexin
V and Dead Cell Kit (Millipore, Billerica, MA, USA) according to
the manufacturer’s instructions. The assay utilizes annexin V to
detect phosphatidylserine on the cell membrane surface of apoptotic
cells and a dead cell marker, 7-aminoactinomycin D (7-AAD), as
an indicator of cell membrane integrity. Briefly, 5×105 cells were
resuspended in 100 μl of culture medium containing 1% FBS and
incubated with 100 μl of Muse Annexin V and Dead Cell Reagent
for 20 min at room temperature in the dark. Annexin V–positive/7-
AAD–negative cells represented early apoptotic cells, while annexin
V–positive/7-AAD–positive cells demonstrated late apoptotic cells.
The cells were quantified using the Muse Cell Analyzer and Muse
analysis software (Millipore).
Change of mitochondrial membrane potential (Δψm). Mitochondrial
membrane potential was determined using Mitochondrial
Permeability Transition Detection kit MitoPT™ JC-1 (AbD Serotec,
Oxford, UK) according to the manufacturer’s instructions. JC-1 dye
exhibits potential-dependent accumulation in mitochondria indicated
by a fluorescence emission shift from green to red (590 nm).
Consequently, mitochondrial de-polarization is indicated by a
decrease in the red/green fluorescence intensity ratio. Briefly, cells
were resuspended at a density 1×106 cells in 1 ml of MitoPT™ JC-
1 solution and incubated for 15 minutes at 37˚C in an atmosphere
containing 5% CO2 in the dark. After incubation, cells were
resuspended in the assay buffer and seeded in a 96-well clear
bottom black plate at a density 1×105 cells/100 μl per well.
Fluorescence was assessed in the microplate reader by measuring
both the monomer (527 nm emission; green) and J-aggregate 
(590 nm emission; red) forms of JC-1 following 488 nm excitation.
Δψm was calculated as J-aggregate to monomer fluorescence
intensity ratio. The membrane potential of mitochondria in treated
cells was expressed as a percentage of that in control cells (100%).
Cell-cycle analysis. Cell cycle distribution was determined using
the Muse Cell Cycle Kit (Millipore) according to the
manufacturer’s instructions. The assay is based on the
measurement of DNA content in nuclei labeled with propidium
iodide (PI). Briefly, 1×106 cells were harvested and fixed with
70% ice cold ethanol at −20˚C for 3-12 h. After washing with
phosphate buffered saline (PBS), cell pellets were resuspended in
200 μl of Cell Cycle Reagent and incubated for 30 min at room
temperature in the dark. Cells were analyzed by Muse Cell
Analyzer and the cell cycle phase distribution was quantified using
Muse analysis software. Graphs were prepared with freeware
Flowing Software 2.5 (http://www.flowingsoftware.com).
Statistical analysis. The results are expressed as means±SD of three
independent experiments. Statistical analysis was performed by
using two-tailed Student’s t-test. p-Values of less than 0.05 were
considered statistically significant. Data were analyzed using the
Prism 5.0 software (GraphPad, La Jolla, CA, USA).
Results
Effect of PJ34 on PARP activity, cell proliferation and
viability. HL60, MOLT4, U937 and K562 cell lines were
exposed to increasing concentrations of the PARP1 inhibitor
PJ34 (0.05 to 1.6 μM) for 48 h. PARP activity was
significantly reduced in cells in a dose-dependent manner
(Figure 1A). In untreated control cells, the highest PARP
activity was observed in the MOLT4 line (~80 U/mg of
protein) and the lowest in the U937 line (~50 U/mg of
protein) (Figure 1A). Cell proliferation and viability were also
inhibited in a dose-dependent manner (Figure 1B and C).
Concentrations of 0.2 μM PJ34 for HL60 and MOLT4 cells
and 0.4 μM for U937 and K562 cells were chosen for further
studies, being the highest concentrations having a relatively
low effect on proliferation and viability (~20% decrease in
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proliferation and ~90% viability) (Figure 1B and C). At these
doses of PJ34, PARP activity was reduced to approximately
15 U/mg of protein in all cell lines (Figure 1A).
Effects of combined PJ34 and vorinostat treatment on cell
proliferation and apoptosis. Cells were treated with appropriate
doses of PJ34 and different concentrations of vorinostat,
causing approximately 20% of total apoptosis (1 μM for HL60
and MOLT4 cells; 2 μM U937 cells and 2.5 μM for K562
cells, data not shown) whether separately or in combination. In
the latter case, PJ34 was added 24 h before vorinostat and then
the cells were exposed to both drugs for the next 24 h. 
At the concentrations used, PJ34 alone did not
significantly influence proliferation in the studied cell lines,
whereas treatment with vorinostat alone caused its significant
reduction in all lines. Treatment with both drugs further
significantly lowered proliferation of HL60, MOLT4 and
K562 cells compared to treatment with vorinostat-alone. In
U937 cells, this effect was not observed (Figure 2).
Treatment with PJ34-alone had no significant effect on
apoptosis in either cell line: the total apoptotic rate ranged
from 4.3% in HL60 cells to 5.5% in MOLT4 cells.
Vorinostat-induced apoptosis was markedly potentiated after
a combined treatment with PJ34 and the percentage of
apoptotic cells nearly doubled, ranging from 37.6% in K562
cells to 48.5% in MOLT4 cells. This effect was, however, not
observed in U937 cells (Figure 3). Similar results were
obtained when early and late apoptotic cells were assessed
separately (data not shown).
Effects of combined PJ34 and vorinostat treatment on
mitochondrial membrane potential. Treatment with PJ34
alone did not cause significant changes in ψm, an early
indicator of mitochondrial involvement in apoptosis, while
vorinostat-alone significantly reduced ψm in all cell lines
compared to untreated cells. The combined treatment of cells
with both drugs resulted in a significant decrease in ψm
compared to treatment with vorinostat alone in all cell lines
except U937 cells (Figure 4).
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Figure 1. Effect of PJ34 on poly (ADP-ribose) (PARP) activity (A),
proliferation (B) and viability (C) of HL60, MOLT4, U937 and K562
cell lines. PJ34 lowered PARP activity, and reduced cell proliferation
and viability in a dose-dependent manner.
Figure 2. Effect of PJ34 and vorinostat (Vor) on the proliferation of
HL60, MOLT4, U937 and K562 cells. Each value is the mean±SD of
three experiments. #Significantly different from the corresponding group
of untreated (control) cells (p<0.04); *significantly different from the
corresponding group of vorinostat-treated cells (p<0.05).
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Figure 3. Effect of PJ34 and vorinostat (Vor) on apoptosis of HL60, MOLT4, U937 and K562 cells. Representative dot plots of annexin V/7-
aminoactinomycin D (7-AAD) apoptotic assay (A) and graph showing the percentage of apoptotic cells (B). Each value is the mean±SD of three
experiments. #Significantly different from the corresponding group of untreated (control) cells (p<0.03); *significantly different from the
corresponding group of vorinostat-treated cells (p<0.03).
Effects of combined PJ34 and vorinostat treatment on the
cell cycle. PJ34 alone did not significantly influence the cell
cycle in the studied lines (Figure 5). After treatment with
vorinostat alone, the percentage of S-phase cells was
significantly reduced in HL60 and U937 lines (Figure 5A-C)
and all cell lines showed an increase in the percentage of
cells in the sub-G1 phase (Figure 5). Compared to the effect
of vorinostat-alone, the combined treatment of cells with
vorinostat and PJ34 resulted in further decrease in the
percentage of S-phase cells in all cell lines and of cells in
the G2/M phase for U937 and K562 lines, while the
percentage of cells in G0/G1 phase was significantly
increased for U937 and K562 cells and of those in sub-G1
phase cells for all except U937 cells (Figure 5).
Discussion
Combining drugs which target DNA repair and epigenetic
control of gene transcription seems to be an encouraging
approach to anticancer treatment. The present study has
demonstrated that combined exposure of human leukemia cell
lines to the PARP inhibitor PJ34 and the HDAC inhibitor
vorinostat results in a significant decrease in cell proliferation,
accompanied by an increase in both early and late apoptosis,
manifested by the loss of mitochondrial membrane potential,
an early event preceding phosphatidylserine externalization
(17, 18), annexin V binding and 7-AAD fluorescence. 
Such effects were similar in three out of the four studied
cell lines: HL60, MOLT4 and K562, but was not observed in
U937 line: as compared to cells treated by vorinostat as a
single agent, combined treatment with vorinostat and PJ34
did not induce significant changes in cell growth, apoptosis
rate and mitochondrial membrane potential. All leukemia cell
lines studied revealed sensitivity to PJ34, manifested by a
dose-dependent decrease in PARP activity. However, in
untreated control cells, PARP activity was the lowest in U937
cells, and this could contribute to unresponsiveness of this
cells to the combined treatment, although the relevant data
seem to be controversial. As demonstrated in other studies on
treatment of cell lines with PARP inhibitors combined with
other anticancer drugs, PARP inhibitor ABT-888 did not
enhance temozolomide activity in U937 cells and in some
primary leukemia cells expressing low PARP activity. On the
other hand, KG1 leukemia cells with low PARP activity
showed a marked potentiation of temozolomide cytotoxicity
in combination with ABT-888 (6). Another PARP inhibitor,
GPI-15427 increased temozolomide and irinotecan activity in
colon cancer xenografts and this effect was not dependent on
PARP activity (19). In our previous study, etoposide-induced
apoptosis of U937 cells was not potentiated after pre-
treatment with HDAC inhibitors, although such potentiation
was observed in HL60 cells (16). 
The different effectiveness of PARP inhibitors may reflect
the variability of cell lines. Leukemia cells display different
phenotypes and diverse chromosomal abnormalities. Some
aberrant genes, especially in cells in acute myeloid leukemia
and myelodysplastic syndromes, are components of the
homologous recombination pathway of double-strand DNA
break repair. Moreover, leukemia cells display error-prone
non-homologous end-joining of double-strand DNA break
repair and mutations in other double-strand DNA break repair
components (20-22). This makes them good candidates for
treatment with PARP inhibitors, however, the response of
different cell lines to PARP inhibitors combined with other
chemotherapeutic agents can also depend upon a variety of
factors, such as drug concentration, exposure conditions and
the sequence of drug administration. In MCF7 cells, the
PARP inhibitor NU1025 increased the antiproliferative effect
of topoisomerase II inhibitor C-1305 when added to the
culture as the second drug, but reversal of the schedule had
the opposite result: the antiproliferative effect of C-1305 was
reduced (23). The combined treatment of leukemia cells with
PARP, HDAC and DNA methyltransferase inhibitors can also
be schedule-specific (8).
PARP inhibitors have been postulated to affect the cell
cycle. As recently demonstrated, PJ34 causes cell-cycle
arrest in various cancer cell lines (24-26). The arrest of cells
at the cell-cycle checkpoints is an event preceding apoptosis
(27). HDAC inhibitors can also influence cell cycle.
Vorinostat has been shown to induce apoptosis of leukemia
cells in the G0/G1 phase of the cell cycle by inducing the
cyclin-dependent kinase inhibitor p21 and to arrest cells in
the G1 phase (28, 29). In our study, PJ34 and vorinostat were
Jasek et al: Combinatorial Effects of PJ34 and Vorinostat on Leukemia Cells
1853
Figure 4. Effect of PJ34 and vorinostat (Vor) on the mitochondrial
membrane potential (ψm) of HL60, MOLT4, U937 and K562 cells. Each
value is the mean±SD of three experiments. #Significantly different from
the corresponding group of untreated (control) cells (p<0.03);
*significantly different from the corresponding group of vorinostat-
treated cells (p<0.04).
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Figure 5. Effect of PJ34 and vorinostat (Vor) on cell-cycle distribution of HL60, MOLT4, U937 and K562 cells. Representative DNA histograms
(A) and graphs showing the distributions of cells in specific cell cycle phases (B, C, D, E). Each value is the mean±SD of three experiments.
#Significantly different from the corresponding group of untreated (control) cells (p<0.05); *significantly different from the corresponding group of
vorinostat-treated cells (p<0.05).
used at concentrations showing low toxicity. At 0.2 and 0.4
μM, PJ34-alone did not induce significant changes in the cell
cycle. The main effect of vorinostat alone and in combination
with PJ34 at the studied concentrations was a significantly
increased percentage of cells in the sub-G1 phase, indicative
of apoptosis. This result fully corresponded to the effect of
the drugs on apoptosis, with all cell lines except U937
showing further significant increase in the number of sub-G1
cells after combined treatment. We also observed an
increased percentage of K562 and U937 cells in the G0/G1
phase after treatment with PJ34 and vorinostat. A similar
effect was reported after prolonged 24-h treatment of K562
cells with vorinostat alone (30).
In conclusion, combination of PARP inhibitors with
HDAC inhibitors can effectively reduce survival of leukemia
cells by inhibiting proliferation and inducing apoptosis, but
this effect may depend on cell type, concentration of drugs
within the range showing less additive toxicity for normal
cells, and administration schedule. Nevertheless, it seems to
be a promising therapeutic strategy for hematological
malignancies.
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